Eli Lilly And Company

Prescryptive Helps Power LillyDirect®, Supporting Direct-to-Patient Access

Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

Lilly declares second-quarter 2026 dividend

Trulicity Market Size to Reach USD 15.30 Billion by 2035 with Strong Demand for Metabolic Treatments | SNS Insider